BACKGROUND: Hen's egg allergy is among the most common food allergies in childhood and predicts later development of allergic disease. The optimal efficacy and mechanism(s) of egg allergen immunotherapy are poorly understood. OBJECTIVE: To enhance immunologic and clinical outcomes of egg oral immunotherapy (OIT) using a conditionally increased dosing strategy. METHODS: In an open-label clinical trial of egg OIT, egg-allergic children ingested daily doses of egg protein that were gradually increased based on the egg white (EW) IgE level. Skin prick test reactivity and EW- and ovomucoid-specific cellular and humoral responses were measured longitudinally. To confirm clinical tolerance, patients underwent double-blinded, placebo-controlled food challenges 1 month after completing the dosing protocol. RESULTS:Children aged 3 to 13 years with characteristics of clinical egg allergy were enrolled. All 6 patients who completed the entire protocol developed clinical tolerance to egg during the study. The median wheal diameter on EW skin prick testing decreased from 10 to 2.5 mm during OIT (P = .03). Both EW and ovomucoid IgE levels significantly decreased during the study (median EW IgE level: from 18.8 kU/L at baseline to 3.9 kU/L, P = .03), and corresponding IgG4 levels increased (median EW IgG4 level: from 0.65 mg/L at baseline to 86.15 mg/L, P = .03). Transient increases were seen in egg-induced interleukin 10 (P = .06) and transforming growth factor β (P = .18) levels, and the ratio of T(H)2:T(H)1 cytokine production was decreased (P = .25). CONCLUSIONS: Egg OIT is associated with tolerance acquisition in children with persistent egg allergy. Individualized dosing regimens may be necessary to achieve a full therapeutic effect in some patients.
RCT Entities:
BACKGROUND: Hen's egg allergy is among the most common food allergies in childhood and predicts later development of allergic disease. The optimal efficacy and mechanism(s) of egg allergen immunotherapy are poorly understood. OBJECTIVE: To enhance immunologic and clinical outcomes of egg oral immunotherapy (OIT) using a conditionally increased dosing strategy. METHODS: In an open-label clinical trial of egg OIT, egg-allergic children ingested daily doses of egg protein that were gradually increased based on the egg white (EW) IgE level. Skin prick test reactivity and EW- and ovomucoid-specific cellular and humoral responses were measured longitudinally. To confirm clinical tolerance, patients underwent double-blinded, placebo-controlled food challenges 1 month after completing the dosing protocol. RESULTS:Children aged 3 to 13 years with characteristics of clinical egg allergy were enrolled. All 6 patients who completed the entire protocol developed clinical tolerance to egg during the study. The median wheal diameter on EW skin prick testing decreased from 10 to 2.5 mm during OIT (P = .03). Both EW and ovomucoid IgE levels significantly decreased during the study (median EW IgE level: from 18.8 kU/L at baseline to 3.9 kU/L, P = .03), and corresponding IgG4 levels increased (median EW IgG4 level: from 0.65 mg/L at baseline to 86.15 mg/L, P = .03). Transient increases were seen in egg-induced interleukin 10 (P = .06) and transforming growth factor β (P = .18) levels, and the ratio of T(H)2:T(H)1 cytokine production was decreased (P = .25). CONCLUSIONS: Egg OIT is associated with tolerance acquisition in children with persistent egg allergy. Individualized dosing regimens may be necessary to achieve a full therapeutic effect in some patients.
Authors: Ariana D Buchanan; Todd D Green; Stacie M Jones; Amy M Scurlock; Lynn Christie; Karen A Althage; Pamela H Steele; Laurent Pons; Rick M Helm; Laurie A Lee; A Wesley Burks Journal: J Allergy Clin Immunol Date: 2006-10-27 Impact factor: 10.793
Authors: R Nickel; M Kulig; J Forster; R Bergmann; C P Bauer; S Lau; I Guggenmoos-Holzmann; U Wahn Journal: J Allergy Clin Immunol Date: 1997-05 Impact factor: 10.793
Authors: Ananth Thyagarajan; Pooja Varshney; Stacie M Jones; Scott Sicherer; Robert Wood; Brian P Vickery; Hugh Sampson; A Wesley Burks Journal: J Allergy Clin Immunol Date: 2010-07 Impact factor: 10.793
Authors: G Patriarca; E Nucera; C Roncallo; E Pollastrini; F Bartolozzi; T De Pasquale; A Buonomo; G Gasbarrini; C Di Campli; D Schiavino Journal: Aliment Pharmacol Ther Date: 2003-02 Impact factor: 8.171
Authors: Corinne A Keet; Pamela A Frischmeyer-Guerrerio; Ananth Thyagarajan; John T Schroeder; Robert G Hamilton; Stephen Boden; Pamela Steele; Sarah Driggers; A Wesley Burks; Robert A Wood Journal: J Allergy Clin Immunol Date: 2011-11-30 Impact factor: 10.793
Authors: François Graham; Natacha Tardio; Louis Paradis; Anne Des Roches; Philippe Bégin Journal: Hum Vaccin Immunother Date: 2017-10-03 Impact factor: 3.452
Authors: Brian P Vickery; Amy M Scurlock; Michael Kulis; Pamela H Steele; Janet Kamilaris; Jelena P Berglund; Caitlin Burk; Anne Hiegel; Suzanna Carlisle; Lynn Christie; Tamara T Perry; Robbie D Pesek; Saira Sheikh; Yamini Virkud; P Brian Smith; Mohamed H Shamji; Stephen R Durham; Stacie M Jones; A Wesley Burks Journal: J Allergy Clin Immunol Date: 2013-12-19 Impact factor: 10.793